Bristol-Myers Squibb Australia News and Activities

Bristol-Myers Squibb Australia is owned by Bristol-Myers Squibb.

Bristol-Myers Squibb is one of the...

• Forbes Global 2000 (#173);
• Fortune 500 (#98);
• Global Fortune 500 (#94);
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Bristol-Myers Squibb is a company listed under the stock ticker BMY (US).

Bristol-Myers Squibb has a direct presence in 21 countries.

Bristol-Myers Squibb has 23 subsidiaries including Bristol-Myers Squibb APAC, Bristol-Myers Squibb Australia and Bristol-Myers Squibb Benelux.

They are in:

• Pharmaceuticals83%
• Biotechnology17%

Acquisition, funding and merger involving Bristol-Myers Squibb.

• Bristol-Myers Squibb has announced the acquisition of 2Seventy Bio  (posted on March 11 2025).
• Bristol-Myers Squibb has announced the acquisition of Karuna Therapeutics  (posted on December 22 2023).
• Bristol-Myers Squibb has announced the acquisition of Mirati  (posted on October 12 2023).

View the org chart displaying its 3 main executives

Most searched biographies at Bristol-Myers Squibb Australia

• Catherine Vaughan, Business Unit Director, Innovative Medicines
• Kaye Grant, Director Strategy and Operations
• Alison Melville, Public Affairs Manager

Popular executive movements at Bristol-Myers Squibb

• Fernando Salinas who was Chief Inclusion & Diversity Officer and Head of HR Commercialization, becomes Chief Talent and Inclusion Officer  (posted on May 27 2025).
• Sandra Leung, Executive Vice President and General Counsel, has left the company  (posted on May 6 2025).
• Cari Gallman, who was Executive Vice President, Corporate Affairs, is promoted to Executive Vice President, General Counsel and Chief Policy Officer  (posted on May 6 2025).

Create your alert
to follow the executive moves at Bristol-Myers Squibb Australia.

Bristol-Myers Squibb has 1,838 competitors including Pfizer (United States (USA)), Johnson & Johnson (United States (USA)) and Sanofi (France).

Popular M&A news in Pharmaceuticals

• Supernus Pharmaceuticals has announced the acquisition of Sage Therapeutics  (posted on June 16 2025).
• Juvenescence has just announced a $76 Million fundraising (posted on May 22 2025).
• Kincell Bio has just announced a $22 Million fundraising (posted on May 22 2025).

Popular contacts in Pharmaceuticals

• Estelle Vester-Blokland - Senior Vice President, Medical and Head, International Markets at Bristol-Myers Squibb
• Amanda Moore - Vice President, Program Leadership and Clinical Operations at Abeona Therapeutics
• Keiichi Ando - Independent Non-Executive Director at Shionogi

Learn more about the Pharmaceuticals industry

Press releases by Bristol-Myers Squibb Australia

Social media about Bristol-Myers Squibb Australia

• Bristol-Myers Squibb Australia on Wikipedia, Google News & Yahoo Finance
• Bristol-Myers Squibb Australia on LinkedIn, Twitter & YouTube